{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:27:34Z","timestamp":1786580854705,"version":"build-2736575974"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NCI Mentored Clinical Scientist Research Career Development Award","award":["1K08CA255465-01A1"],"award-info":[{"award-number":["1K08CA255465-01A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic lymphoma kinase (ALK) fusions are established oncogenic drivers and therapeutic targets in multiple malignancies, including non-small cell lung cancer, but are rare in colorectal cancer (CRC). Although ALK fusions in CRC have been associated with sensitivity to ALK inhibitors, their broader genomic context remains incompletely defined. We aimed to characterize the prevalence, clinicogenomic features, and therapeutic implications of ALK fusions in advanced CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Comprehensive genomic profiling using hybrid capture-based next-generation sequencing was performed on 56\u00a0206 advanced CRC tumors to identify alterations, including ALK fusions. Microsatellite instability (MSI)\/mismatch repair (MMR) status, tumor mutational burden (TMB), genomic ancestry, COSMIC trinucleotide signatures, and homologous recombination deficiency (HRD) signatures were derived from sequencing data. PD-L1 expression was assessed by immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ALK fusions were identified in 63 tumors (0.1%). Compared with ALK fusion-negative CRC, ALK fusion-positive (ALKfus+) tumors demonstrated enrichment for MSI-high\/MMR-deficient status and high TMB, with numerically higher PD-L1 expression. In contrast, canonical CRC driver alterations were markedly depleted, including KRAS, APC, and PIK3CA mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ALK fusions define a rare but biologically distinct subset of CRC characterized by frequent MSI-high\/MMR-deficient status and a unique genomic landscape. These findings support comprehensive genomic profiling to identify ALK fusions in CRC, which may inform the use of ALK-directed therapies, and highlight the frequent co-occurrence of MSI-high disease within this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag308","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:16:51Z","timestamp":1786101411000},"source":"Crossref","is-referenced-by-count":0,"title":["Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-4642","authenticated-orcid":false,"given":"Xuanyi","family":"Li","sequence":"first","affiliation":[{"name":"Yale Cancer Center , New Haven, CT 06510,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Yasin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-6246","authenticated-orcid":false,"given":"Dean C","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc , Boston, MA 02210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc , Boston, MA 02210,","place":["United States"]},{"name":"Upstate Medical University Syracuse, NY 13210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-0128","authenticated-orcid":false,"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[{"name":"Yale Cancer Center , New Haven, CT 06510,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2026081219362913200_oyag308-B1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"2026081219362913200_oyag308-B2","doi-asserted-by":"publisher","first-page":"113975","DOI":"10.1016\/j.ejca.2024.113975","article-title":"A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness","volume":"202","author":"Yoshino","year":"2024","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2026081219362913200_oyag308-B3","doi-asserted-by":"publisher","first-page":"102700","DOI":"10.1016\/j.ctrv.2024.102700","article-title":"Current advances in targeted therapy for metastatic colorectal cancer - clinical translation and future directions","volume":"125","author":"Johnson","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026081219362913200_oyag308-B4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1158\/2159-8290.CD-12-0009","article-title":"ALKoma: a cancer subtype with a shared target","volume":"2","author":"Mano","year":"2012","journal-title":"Cancer Discov"},{"key":"2026081219362913200_oyag308-B5","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3390\/cancers11081074","article-title":"The transcriptional roles of ALK fusion proteins in tumorigenesis","volume":"11","author":"Ducray","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026081219362913200_oyag308-B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"Npj Precis Oncol"},{"key":"2026081219362913200_oyag308-B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"2026081219362913200_oyag308-B8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: from function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026081219362913200_oyag308-B9","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"2026081219362913200_oyag308-B10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"2026081219362913200_oyag308-B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"2026081219362913200_oyag308-B12","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081219362913200_oyag308-B13","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081219362913200_oyag308-B14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026081219362913200_oyag308-B15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081219362913200_oyag308-B16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children\u2019s oncology group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026081219362913200_oyag308-B17","author":"Research C for DE and","year":"2024"},{"key":"2026081219362913200_oyag308-B18","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.tranon.2021.101191","article-title":"Will the clinical development of 4th-generation \u201cdouble mutant active\u201d ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK\u2009+\u2009NSCLC?","volume":"14","author":"Ou","year":"2021","journal-title":"Transl Oncol"},{"key":"2026081219362913200_oyag308-B19","doi-asserted-by":"publisher","first-page":"146212","DOI":"10.1016\/j.ijbiomac.2025.146212","article-title":"Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131","volume":"321","author":"Zhao","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"2026081219362913200_oyag308-B20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"2026081219362913200_oyag308-B21","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1158\/1078-0432.CCR-20-4073","article-title":"Molecular characterization and therapeutic targeting of colorectal cancers harboring receptor tyrosine kinase fusions","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026081219362913200_oyag308-B22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41698-024-00598-7","article-title":"Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis","volume":"8","author":"Li","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026081219362913200_oyag308-B23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"key":"2026081219362913200_oyag308-B24","doi-asserted-by":"publisher","first-page":"oyae020","DOI":"10.1093\/oncolo\/oyae020","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors show activity in colorectal cancer with ALK rearrangements: case series and literature review","volume":"30","author":"Hu","year":"2025","journal-title":"Oncologist"},{"key":"2026081219362913200_oyag308-B25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026081219362913200_oyag308-B26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2026081219362913200_oyag308-B27","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2026081219362913200_oyag308-B28","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"2026081219362913200_oyag308-B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2026081219362913200_oyag308-B30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite Instability-High cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn JMD"},{"key":"2026081219362913200_oyag308-B31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2026081219362913200_oyag308-B32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2026081219362913200_oyag308-B33","doi-asserted-by":"publisher","first-page":"oyaf089","DOI":"10.1093\/oncolo\/oyaf089","article-title":"Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers","volume":"30","author":"Jeon","year":"2025","journal-title":"Oncologist"},{"key":"2026081219362913200_oyag308-B34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"2026081219362913200_oyag308-B35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"2026081219362913200_oyag308-B36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human Colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"2026081219362913200_oyag308-B37","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1053\/j.gastro.2015.06.047","article-title":"Genetics and genetic biomarkers in sporadic colorectal cancer","volume":"149","author":"Carethers","year":"2015","journal-title":"Gastroenterology"},{"key":"2026081219362913200_oyag308-B38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/gcc.22539","article-title":"Mutation analysis of adenomas and carcinomas of the colon: early and late drivers","volume":"57","author":"Wolff","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"2026081219362913200_oyag308-B39","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1158\/1078-0432.CCR-15-3000","article-title":"Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target","volume":"22","author":"Yakirevich","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026081219362913200_oyag308-B40","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/PAS.0000000000001512","article-title":"Colorectal adenocarcinomas harboring ALK fusion genes: a clinicopathologic and molecular genetic study of 12 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2026081219362913200_oyag308-B41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0002-9440(10)64945-0","article-title":"ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)","volume":"156","author":"Colleoni","year":"2000","journal-title":"Am J Pathol"},{"key":"2026081219362913200_oyag308-B42","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.21037\/tlcr-20-1049","article-title":"Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report","volume":"9","author":"Wu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2026081219362913200_oyag308-B43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13000-016-0586-z","article-title":"Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report","volume":"11","author":"Tateishi","year":"2016","journal-title":"Diagn Pathol"},{"key":"2026081219362913200_oyag308-B44","doi-asserted-by":"publisher","first-page":"1123378","DOI":"10.3389\/fonc.2023.1123378","article-title":"Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib","volume":"13","author":"Shahab","year":"2023","journal-title":"Front Oncol"},{"key":"2026081219362913200_oyag308-B45","doi-asserted-by":"publisher","first-page":"e15568","DOI":"10.1200\/JCO.2022.40.16_suppl.e15568","article-title":"Clinical and molecular characterization of fusion genes in colorectal cancer","volume":"40","author":"Karan","year":"2022","journal-title":"JCO"},{"key":"2026081219362913200_oyag308-B46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2022.04.024","article-title":"Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening","volume":"170","author":"Delaye","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026081219362913200_oyag308-B47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrc3947","article-title":"The emerging complexity of gene fusions in cancer","volume":"15","author":"Mertens","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2026081219362913200_oyag308-B48","doi-asserted-by":"publisher","first-page":"e2100477","DOI":"10.1200\/PO.21.00477","article-title":"Clustered 8-oxo-guanine mutations and oncogenic gene fusions in microsatellite-unstable colorectal cancer","volume":"6","author":"Madison","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026081219362913200_oyag308-B49","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1186\/s12885-025-14117-9","article-title":"Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach","volume":"25","author":"Pellatt","year":"2025","journal-title":"BMC Cancer"},{"key":"2026081219362913200_oyag308-B50","doi-asserted-by":"publisher","first-page":"1158417","DOI":"10.3389\/fonc.2023.1158417","article-title":"The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Kalra","year":"2023","journal-title":"Front Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag308\/70529669\/oyag308.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag308\/70529669\/oyag308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag308\/70529669\/oyag308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:36:35Z","timestamp":1786577795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag308\/8753977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag308","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag308"}}